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This paper identifies, characterises and analyses six evolving regenerative business (RM) 
models in the UK based on 10 cases we studied.  Our conceptual framework extracts four key 
elements from contemporary business model and value chain literature; 
architecture/structure, value creation and extraction, networks and linkages, and 
governance.  Using the case study method, we identified the following business models: 
materials and service provision; early exit: Phase I/II; manufacturing and scale up; 
translational services; virtual; and integrated. All the business models are still pre-revenue, 
except for manufacturing and scale up which generates revenue from contract manufacturing 
therapies for clinical trials.  The RM sector is still evolving and consequently the business 
models are still in flux.  Two key challenges for the sector are scalability and sustainability, 
which creates challenges for pre-emptive policy and practice interventions. We conclude that 
pre-emptive policy design should support value chain upgrading, paying particular attention 
to short, medium and long-term sustainability of the RM innovation eco-system, especially 
evolution of a broad base of SMEs that can take over when public funding is withdrawn. A 
proportionate and adaptive regulatory environment will be critical to supporting evolving 




Regenerative Medicine (RM) is recognised as one of the UK’s Eight Great Technologies 
(Department for Business, Innovation and Skills (BIS), 2013), with claims to solve currently 
intractable health needs, create new industries and contribute to the bioeconomy.  Its 
significance stems from its “claim to cure” by restoring normal cell, organ and tissue form and 
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function (Wang, 2013), bringing benefits to patients and health service providers. RM 
therapies could be one-off, providing a cure for a disease, or repeated at regular intervals for 
chronic conditions like diabetes.  Therapy may be: (i) autologous, where a patient’s cells are 
harvested, manipulated in a laboratory, factory or clinical setting and reintroduced into the 
same patient, or (ii) allogeneic, where a patient receives cells manufactured in a central 
facility from a single donor, serving large numbers of patients over a large geographical area 
(Couto et al, 2012; Omidvar et al., 2014).  Key determinants of therapy choice and hence 
business models are disease area, and availability of cell culture starting materials, which 
drive strategic choices for production, process control, logistics, and regulatory framework 
applied (Franklin and Kaftantzi, 2008).  
The Cell and Gene Therapy Catapult (CGTC) reports a 60% increase in the licenced good 
manufacturing practice (GMP) accredited production space (8 000m2 by 2019), and 30% 
increase in employment, making the UK the most advanced RM region in Europe1.  The CGTC 
CEO reported in an interview with Ben Hargreaves that the industry grew from a few firms to 
over 70 by 2018 and raising of £2.5 billion2.  However, the UK and European RM terrain has 
been dominated by small to medium enterprises (SME) and academic research institutions 
(BIS, 2011).  Pathways to market are uncertain and regulation is not always proportionate and 
adaptive to RM needs (Tait and Banda, 2016), constraining resource-poor SMEs from 
developing radical innovations. The UK House of Lords Science and Technology Committee 
Regenerative Medicine Report (HoL S&TC, 2013) and Omidvar et al., (2014) identified the 
following barriers to translation of the UK’s scientific strength in RM ‘from bench to bedside’: 
regulation, intellectual property (IP) protection, clinical trials design, manufacturing capacity, 
National Health Service (NHS) procurement strategies, National Institute for Health and Care 
Excellence (NICE) evaluation processes, and lack of innovative funding models for 
commercialisation.  The UK regulators have reported adopted the fellow traveller concept, 
where they continuously learn from innovators and adapt regulatory requirements to the 
idiosyncrasy of the RM sector (Banda et al, 2018).  Thus, RM integration into healthcare value 
chains requires better conceptualisation of the complexities of its business models.  We use 
the business model concept as a heuristic device and sense-making tool that can help in 
designing context-specific policy, regulatory and investment intervention packages that can 
facilitate better commercial development and risk management.  Although ordinarily used for 
well-established sectors/businesses, we apply the business model concept to RM, an 
emerging life sciences radical innovation, where innovators face a dual challenge of inventing 
new business models and value chains with no precedence, whilst concurrently developing 
radical innovations (Tait & Wield in this issue).  
We consider the value and capacity of conventional business model approaches to deal with 
the RM complexities.  Our study uses ten case studies based on research carried out between 
2015 and 2017 that built on previous work by Mittra et al (2014) and Omidvar et al (2014).  
The overall objective of this paper is to identify, characterise and analyse a typology of 
emerging UK RM business models in recent years.  Using a conceptual framework developed 
from business model and value chain theory, we investigate the architecture/structure, value 
                                                          
1 https://ct.catapult.org.uk/news-media/manufacturing-news/research-highlights-uk-growing-manufacturing-
industry  accessed 6 July 2019 
2 https://www.biopharma-reporter.com/Article/2018/11/26/UK-cell-and-gene-therapy-ecosystem-second-to-
none accessed 6 July 2019 
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creation and extraction, networks and linkages, and governance structures that characterise 
evolving RM business models.  Our contribution to literature is two-fold. First, we apply ex-
ante the business model concept to RM, an emerging radical innovation with gaps in its value 
chains, that needs to negotiate complex ecosystem influences, including regulatory systems 
and standards, financial support systems, and new market dynamics (Banda et al, 
forthcoming) and with no clear route to market.  Second, we identify six business models that 
describe the logic of the firms in the sector, and at a macro-level we show the architecture of 
the UK RM sector through the inter-linkages of the six business models. 
The paper is structured as follows. In section 2 we discuss the methods used, and in section 3 
we review and analyse the literature on the business model concept and the challenges of 
applying it ex ante to regenerative medicine.  In section 4 we present and discuss the six UK 
RM business models we identified, and conclude with section 5.  
2. Methods 
This study examined the dynamics of innovation within RM and the broader institutional 
readiness of the UK health system to adopt RM using the case study approach (Yin, 2003),  
focusing on the six RM business models identified (Table 1).  The study ran for over two and 
a half years (2015-17) and we approached 20 firms/organisations of which 10 agreed to 
participate; we refer to these as cases.  Access for interviews was difficult because of 
sensitivities on proprietary knowledge and competitive advantages.  The 10 UK RM cases’ 
activities ranged from immunotherapies to tissue regeneration.  We held two rounds of semi-
structured interviews with the 10 cases. The first round of interviews with all 10 cases lasted 
from one to two and half hours depending on available time; the second round, to check the 
validity of our interpretation of the identified business models and company activities, was 
done telephonically with interviewees from eight out of the ten cases.  All interviews except 
for one case were audio recorded after seeking informed consent from the interviewees.  
Notes were taken for the case that was not audio-recorded.  The audio recordings were 
transcribed verbatim and coded manually to identify key themes we used to characterise and 
analyse the six business models and factors driving the strategic choices for the cases.   
During the interviews, we sought to understand the interviewees’ perception of their 
business model(s), what drove it, their organisational structure, and their unique product 
value proposition.  We also sought to understand who manufactured the RM therapies and 
how they were manufactured, how the company navigated the regulatory framework, how 
they sourced funding and any networks and linkages that were important for them.  We 
designed this to understand the nature of RM value chains, key linkages and what influenced 
collaborations. Names of respondents and cases have been anonymised as promised during 
the interviews. 
Table 1.  Type of organisations, therapy areas and stages, and funding sources of the 10 case 
studies. 
Type of Organisation and Therapy Area  Funding Sources Therapy Stage 





Firm B: autologous – Immunotherapy Public + Private Equity + 
Financial Institutions.  
£5 million 
Clinical Trials 
Firm C: autologous –  Cell therapy and   
Surgery  
Grants and Private 
Equity 
Clinical Trials 
Firm D: autologous –  Tissue engineering 
and Surgery 
Grants and Private 
Equity. £8 million 
anticipating Euro 7 
million. 
Clinical Trials /  
Compassionate Use 
University Spinoff: allogeneic – Cell 
therapy 
Grants Animal Studies 
Firm E: drug discovery and contract 
manufacture 
Grant + Others CMO*  
Firm F: allogeneic – Cell therapy Private Equity and 
Grants.  £40 million 
Clinical Trials 
Public Organisation: allogeneic – Cells and 
organs 
Public CMO* 
Firm G: allogeneic – Cell therapy Private Equity + Public 
funds (£52 million). Burn 
rate £1 m per month 
Clinical Trials – Specials / 
Unlicensed 
Research Consortium: allogeneic – Cell 
therapy 
Grants: ~ £15 million 
over 8 years 
Pre-Clinical 
* Contract Manufacturing Organisation 
3. The business model concept and its application to regenerative medicine 
We built on the business model and value chain literature to construct the conceptual 
framework we use to identify, characterise and analyse the six RM business models in the ten 
cases we studied.  There is generally lack of consensus on the business model concept’s 
theoretical underpinnings, which attracts criticism because of interpretation and application 
fluidity across diverse disciplines (Al-Debei and Avison, 2010; Chesbrough and Rosenbloom, 
2002).  However, there is general acceptance of its utility as a framework for understanding 
the logic of an enterprise.  It helps to explain how a business with an attractive value 
proposition, creates and extracts value by selecting a route to market that results in 
sustainable revenue inflows and profitability (Al-Debei and Avison, 2010; Osterwalder et al, 
2005; Santos et al, 2009).  The concept has mostly been applied ex-post, that is after 
resolution of technology, value chain, regulation and market development challenges.  It is 
more complex to apply the concept ex-ante to RM, an evolving radically innovative sector 
with value chain gaps, problematic regulatory precedents (Tait and Banda, 2016), few 
products on the market and limited revenue inflows to make the business attractive to early 
stage funders.  Cognisant of these complexities, and building on business model literature, 
we identified four elements we discuss below to construct a conceptual framework that we 
apply ex ante to RM business model.  None of the current business model frameworks is able 
to explain in a robust manner the logic of this pre-revenue sector, as value creation and 




Osterwalder et al (2005) and Trimmers (1998) use the term architecture in their definition of 
business models, and Amit and Zott (2001) use structure to articulate how firms create and 
deliver value (Teece, 2010).  Architecture and structure relate to form and function in biology 
or engineering for example, and represent a stable frame upon which related elements can 
be attached, organised or made sense of.  Osterwalder et al’s (2005) business model canvas 
uses this approach to distinguish activities relating to cost structures (key partners, key 
activities and value proposition that straddle revenue streams) and the revenue streams 
themselves (customer relationships and segments, and channels).  Thus, the business model 
canvas provides a logical ‘structure or frame’ for organising cost and revenue drivers for a 
firm.  Strategies deployed by management in executing these activities determine how good 
a firm is at creating and extracting value compared to its competitors.  Trimmers (1998:4) 
uses a similar approach to define business models for electronic markets as “An architecture 
for the product, service and information flows, including a description of the various business 
actors and their roles, a description of the potential benefits for the various business actors, 
and a description of the sources of revenues”. 
Osterwalder et al’s (2005) business models canvas cannot be applied to RM because although 
it captures RM cost structure/architecture of the business, it faces challenges because there 
are no revenue streams as products have not yet reached the market.  All other business 
model definitions face this challenge when applied to pre-revenue enterprises, especially 
those with no regulatory or reimbursement precedence.  Thus in our conceptual framework, 
we adopt the architecture/structure element to, in the broadest sense, describe how RM 
enterprises are organised and how they may create and extract value in the future through 
potential revenue. 
Value creation and extraction 
How to create, capture and deliver value is a common element across all business model 
definitions (Al-Debei and Avison, 2010; Teece, 2010) and we consider value one of the core 
elements of our conceptual framework.  The notion of “economic value” as profits or return 
on investment is predominant, hence the allusion to value creation, value capture and value 
chains.  Linder and Cantrell’s (2000) focus on the value proposition and Osterwalder et al’s 
(2005) treatment of the value proposition and value configuration highlight the importance 
of economic value to business models.  Other authors use: value proposition and strategic 
objectives (Weill and Vitale, 2002); value model (Petrovic et al, 2001); value offering (Gordjin, 
2002); customer value (Afuah and Tucci, 2003); and value architecture. Whilst it is easy to 
demonstrate economic value for established industries, for RM the task is difficult because 
products are still in early development or clinical trials, and supported largely by public 
research funding.  Without reimbursement from approved products, economic value remains 
speculative even without considering the wider societal values (Mittra, 2016) generated by 
reducing recovery times, freeing up hospital space, enabling people to work, and reducing 
pressures on carers. Thus for RM, demonstrating economic value creation and extraction 
especially to investors is a major challenge, one that is faced by most disruptive innovation 
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technology developers with speculative (?) business models with gestation periods of 10-15 
years or more.  Value, the second element of our conceptual framework, has significant 
funding and strategy implications for how healthcare systems will negotiate expensive future 
payments for therapies with claims to cure. 
Networks and Linkages 
We also build on Amit and Zott (2001), who incorporated Porter’s (1985) value chain concept, 
including innovation and the economics of transaction costs into their analysis.  Santos et al 
(2009) however criticised Amit and Zott (2001) and Zott and Amit (2008) for omitting the 
pivotal role played by relationships in intra and inter-firm linkages and constraints within and 
outside an organisation’s system (Figure 1).  Inter-firm linkages are critical for resource 
constrained RM SMEs, which cannot engage in all technological and regulatory learning 
necessary to bring a product to market, and therefore depend on external firms/organisations 
to procure products and services.  Consequently RM business models will value external 
linkages which are critical for information flows (Trimmers, 1998), technology flows, and 
networks of partners and relational capital (Osterwalder et al, 2005), in addition to special 
roles and relationships amongst customers, partners and suppliers (Trimmer, 1998; Weill and 
Vitale, 2002).  These activities require negotiating new networks and linkages, and value chain 
integration, which could lead to new organisational structures (Perkmann and Spicer, 2010), 
as various actors provide information, money, products and services flows (Figure 1). 
Building on the value of networks and linkages, we are interested in the five-way relationships 
between RM-Innovators, their suppliers, other RM-innovators, regulators, patient/clinical 
settings, and investors’ linkage dynamics.  As figure 1 illustrates, the link between RM 
innovators and patients/clinical settings is the claim to cure with important linkages required 
for therapy adoption in order to maximise therapy utility. The link between RM-innovators 
and regulators is assurance of therapy safety and efficacy, which relate to macro-level 
governance issues embodied in cGMP (current Good Manufacturing Practice) and other 
regulations.  Business viability and sustainability, economic value creation and extraction, as 
well as return on investment are the focus of the linkages between investors and RM 
innovators.  RM-innovator to RM-innovator linkage covers competition, collaboration and 
value chain integration with the consequent micro-level value chain governance issues 
discussed under governance. The linkage between suppliers and RM-innovators is important 
for knowledge and product flows.  As they interact, suppliers and innovators exchange inputs 
and there are opportunities for technological learning as RM innovators are integrated into 
their suppliers’ value chains.   In the next section, we focus on regulation and value chain 
governance. 
Figure 1: Linkages among RM innovators, investors, regulators, and the patient/clinical 






In our conceptual framework, the three elements of architecture/structure, value chain 
creation and capture, and networks and linkages are brought together by RM business 
governance at macro and micro levels including regulation of therapies and value chain 
governance respectively (Figure 1).  Definitions of business models are applied mostly to 
sectors with light-touch regulation, omitting regulatory influence on manufacturing and 
quality assurance costs, and hence therapy profitability and firm viability.  Tait and Banda 
(2016) and Tait, Banda and Watkins (2017) argue that proportionate and adaptive governance 
of innovative technologies is important in the early stages to allow many innovations to 
flourish to develop innovations with greatest value.  These regulatory intricacies and 
complexities open up opportunities for early start RM businesses to engage in consultancy 
for latecomers. 
In our conceptual framework, for firm-level governance, we adopt Gereffi et al’s (2005) five 
value chain governance structures: markets; modular value chains; relational value chains; 
captive value chains; and hierarchy value chains.  Gereffi et al (2005;86) describe market 
governance as the situation where information exchanged is not complex and transactions 
are easily governable, whereas modular value chains arise when the nature of the product is 
RM Innovator 




• Value Chain Integration 
• Micro-governance Issues 
• Clinical Trials 
• Therapy Safety 
• Therapy Efficacy 
• cGMP 
• Claim to Cure 
• Therapy Adoption 
• Therapy utility 
• Economic Value Creation 
• Business Viability 
• Business Sustainability 
• Return on Investment 
Suppliers 
• Start-up Materials 
• Technological Skills 
• Therapy Development Skills 
• Value Chain Integration 
• Micro-governance Issues 
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modular and specifications are codified which allows standards to reduce transaction costs 
and variation.  Relational value chains on the other hand arise when product specifications 
are not codified leading to a greater reliance on tacit knowledge and mutual dependence.  
This is likely to be the situation with RM as the knowledge is a mix of codified and tacit 
knowledge. The third form is the captive value chain, which arises when products can be 
codified but are complex and supplier competence is low.  In this case, value chain governance 
causes the lead firm to lock out others from receiving benefits of their first mover investment 
in development efforts.  However, the challenge for RM is that SMEs do not have huge 
financial resources to exert lead firm influence on their suppliers.  The fifth type of value chain 
governance is hierarchy when a triage of factors coincide; products are complex, their 
specifications cannot be codified, and there are no capable suppliers.  This forces lead firms 
to develop in-house these capabilities, allowing the firm to easily exchange tacit knowledge 
and better manage intellectual property.  This is not yet feasible for RM SMEs, as they do not 
possess the resources to develop all capabilities in-house.  Prevalent value chain governance 
in RM is therefore likely to be relational (Figure 2). 
4. Findings and Discussion 
We identified six RM business models used by the 10 cases we studied, all pre-revenue firms 
except for CMOs (Table 1).  In Figure 2, we have, for convenience and simplicity depicted a 
linear development of RM technologies from pre-clinical to clinical adoption, although we 
recognise that innovation is more complex, messy and iterative than this.  The ten cases we 
studied encompassed a broad range of activities spanning pre-clinical work, translation and 
early manufacturing and clinical trials.  Four cases were developing autologous therapies; four 
cases were developing allogeneic therapies, and one was involved in conducting animal 
studies for bone healing.  The tenth case was a CMO developing cells and tissue to be used to 
generate data for drug discovery.  None of the ten cases had obtained market authorisations 
in the UK or elsewhere.  Two cases were CMOs and therapy developers assisting other firms 
involved in Phase 1 clinical trials.  Table 1 shows that funding for the cases came from public 
sources in the form of grants and equity from philanthropic funders/business angels as well 
as UK and regional governments. The majority of activities were in rare disease indications, 
which present clinical trial recruitment challenges (Banda et al, forthcoming).  We analysed 
RM business models using our conceptual framework, composed of four elements; 
architecture/structure, value creation and extraction, networks and linkages, and 
governance. 
 




4.1 Materials and Service Provision Model 
Our analysis of the 10 cases showed that although none had a product on the market, they 
have suppliers of inputs, equipment and knowledge for therapy development and clinical 
trials.  These activities illustrate the Materials and Service Provision Business Model (Figure 
2), composed of firms or organisations which through linkages with RM innovators supply 
biomaterials, cell culture and reagents, machinery and equipment, quality assurance and 
analytical services.  Value is created and extracted from development and clinical trial 
activities and these actors have broad product portfolios spanning other life science 
experimental sectors.   
We identified three representative categories; first, traditional suppliers of cell culture starter 
material, reagents and culture media; second, suppliers of RM therapy production machinery 
and equipment, and, third, RM innovators intending to use RM techniques to supply cells and 
tissue for pharmaceutical drug discovery and toxicology R&D processes (Figure 2).  
The media and reagents suppliers’ small-volume, high-value product business model explains 
the huge cost driver of these inputs for RM as reported by all ten cases.  RM organisations 
thought more competition could lower this aspect of manufacturing costs, or alternatively, 
reflecting the hierarchy value chain governance, they could bring in-house culture media and 
reagent manufacturing capabilities.  However, due to resource limitations they still rely on 
traditional suppliers - demonstrating relational value chain governance.  
Suppliers of manufacturing and imaging equipment are key linkages and knowledge exchange 
actors with RM innovators.  Emphasising the importance of networks and linkages, specialist 
RM therapy equipment development, as one case we studied showed, requires co-designing 
with machine developers and fabricators an activity that engenders bi-directional learning 
Manufacturing and Scale Up Business Model 
Early Exit: Phase I/II Business Model 
Material and Service Provision Business Model 
Integrated Business Model 
Virtual Business Model 
Pre-Clinical 
Scale Up/Out; Translational &  
Regulatory Processes  
Clinical Adoption 
Translational Services Business Model 
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between therapy developers and equipment manufacturers.  This company was not 
interested in capturing IP on the developed machinery and equipment because they claimed 
that their competitive advantage was in delivering innovative immunotherapies. 
In the third category, recognising that RM therapies are a long way from reimbursement, one 
company was both a CMO and therapy developer and was targeting early revenue generation 
by using RM techniques to generate data for pharmaceutical firms for drug modelling, 
toxicology and stratified medicine.  The respondent from that case reported that: 
“… one of the things which I’m very keen to do is … build up the value chain so 
that we can … take stem cells, … make them into a particular lineage, …do the 
assay, … [toxicology] test and … get data. … we can therefore investigate new 
drugs and screen against large libraries which is traditional drug discovery. 
…But you can do …other things, which relate to stratified medicine, and this is 
where I particularly want to go…“ (CEO, CMO and therapy development 
organisation, 2015). 
The respondent reported that linking RM to stratified medicine accelerates development of 
biomarkers for targeting drugs to specific patient cohorts, which can lead to better clinical 
trial design for new drugs, drastically reducing the cost of clinical trials and leading to better 
clinical outcomes for responders.  By integrating early RM activities into traditional pharma 
value chains, this organisation hopes to create and capture value at the early stages of the 
value chain and then re-invest the proceeds into future RM therapy developments.  This 
project was still at the planning stage, but it highlighted the importance of networks and 
linkages in understanding the evolving business models and value chains. 
4.2 Early exit phase I/II business model 
The Early Exit Phase I/II Business model includes firms or organisations focusing on early stage 
RM therapy development and exiting the RM value chain by selling off IP or de-risked 
products. Their strategic intent is value creation through de-risking early stages of RM therapy 
development, demonstrating proof of concept, safety and efficacy (clinical trial phases I/II) 
and taking IP rights over innovative products and processes.  Value appropriation arises 
through linkages with big pharma or biotechnology organisations.  This model occurred in two 
university spin-off cases and a small cell therapy-manufacturing firm as reflected in this quote:  
“The original idea with [firm x] at the start was the classic idea of develop 
something to a certain point and then sell it to big pharma” (CEO, Cell Therapy 
Manufacturing Firm, 2015).   
A company with a broad product portfolio, also developing platform technologies, was 
interested in this approach as they intended to use IP sell-offs and out-licenced platform 
technologies to generate revenues which could be re-invested in the firm.  Our study showed 
that a key driver of this business model was financial resource constraints – inability to raise 
patient capital, and general acknowledgement that RM products will not generate revenue in 
the short to medium term.  In as much as there is a strategic focus to monetise IP, Pisano 
(2006) cautions that although there was IP monetisation in the biotech industry since the 
1970s, it takes a long time for investors to get returns on investment.  A key challenge for the 
sector is that the RM product is very close to nature and presents patentability challenges, 
whereas other IP assets such as trademarks, copyright and utility models can deliver cashflow 
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generating assets. It is important to note that there are academics who are only interested in 
developing therapies but  not entrepreneurship. 
Our study indicated significant challenges to integrating RM and pharmaceutical business 
models.  In Biotech, Li (2007) critiqued Pisano (2006) for neglecting the interplay between 
traditional pharma and biotech industries as a key source of financial flows for the survival of 
the biotech industry.  However, for RM, both the business models and type of therapy are 
disruptive for traditional pharma. Better-formulated strategies that take account of long 
product gestation periods and value creation dynamics, nature of linkages and the 
idiosyncrasies of RM and pharma are necessary as illustrated in this remark:  
“We behaved like a medical device company and tried to license the product 
[skin cell therapy] to medical device companies …. their product cycle was 
really short and they couldn’t understand … why this was going to take so long 
[and] … involve large clinical trials … when they [were] used to making medical 
device products, and shipping … within months or early years. ….Then we 
suddenly decided, you know, we are more like a pharmaceutical [firm] in 
terms of our development cycle”  (CEO, Cell Therapy Manufacturing Firm, 
2015).   
The dilemma faced by the quoted entrepreneur highlights the complexity of aligning the four 
elements (architecture/structure; value creation and capture; linkages and networks; and 
governance) of new business models with established business models.  A common thread 
that emerged during the study was that RM value chains are difficult to integrate into 
contemporary pharmaceutical value chains. In their analysis of stratified medicine, Mittra and 
Tait (2012) observed that where new technologies offered both opportunities and challenges 
to conventional pharmaceutical R&D, there was need to manage complex regulatory systems, 
sales, logistics and re-imbursement and to negotiate inter-sectoral collaborations with 
companies operating different business models. Although Academic Drug Discovery 
Centres/Consortia may be worth considering here, their utility for the RM sector is currently 
limited because, first RM has a niche focus, and second, our research indicates that being a 
pioneer has strategic and competitive advantage and therefore collaborations are difficult for 
emerging fields. 
4.3 Manufacturing and Scale Up Business Model 
The Manufacturing and Scale Up Business Model comprises firms or organisations which 
create and extract value by investing in cGMP compliant RM facilities and contract 
manufacturing therapies.  They specialise in therapy production optimisation for clinical trials 
only.  This business model can also be adopted by firms or organisations with in-house 
production needs, using excess production capacity for contract manufacturing as a strategic 
choice.  The manufacturing and scale up business model is central to the other five RM 
business models (see Figure 1), because it is a critical linkage in the RM value chain that 
connects upstream therapy development actors with downstream translational activities in 
clinical trial design and management as well as clinical adoption.   
Our study indicated that the UK did not have capacity to produce therapies at scale for clinical 
use.  As at 2014, the Cell and Gene Therapy Catapult (CGTC) reported that the UK had 13 
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cGMP (current Good Manufacturing Practice) RM facilities with 52 clean rooms (CGTC, 2014). 
An analysis of these cGMP RM facilities showed that they fall into four categories; academic, 
public sector, private sector and charities.  Eight of the thirteen-cGMP RM facilities are in 
either the academic or public sector. Other publicly (and research grant) funded institutions 
used by the rest of the cases we studied in early translational stages included Guy’s & St 
Thomas’ Hospital, NHSBT – Speke; Scottish Centre for Regenerative Medicine (Roslin Cells and 
SNBTS) and Great Ormond Street Hospital Cellular Therapy Laboratories.  The other players 
with RM cGMP facilities included academic facilities at Kings College London, Imperial College, 
and University College London (UCL); and charities such as Cancer Research UK (CGTC, 2014).   
This underscores the observation that SMEs cannot afford to invest early in cGMP facilities, 
as reported by an autologous immunotherapy case: 
[The CGTC]… de-risks the manufacturing… [and they]… do not have to invest 
in building [their] … own [cGMP] building … So [they] push the risk, [of] 
invest[ing] …in a building, further down the development pathway. 
Another RM case with a broad product portfolio, which had contracted out their cell 
manufacturing to an entity that shut down, indicated that they would use the CGTC Stevenage 
facility, demonstrating that government’s investment in innovation infrastructure (Banda et 
al, forthcoming) is welcomed by the sector.  However, if not carefully considered such 
interventions can in the short-term crowd out Small to Medium Enterprises (SMEs) from the 
innovation ecosystem, creating challenges when funding is later withdrawn (Banda et al 
forthcoming).  Innovation anchor institutions such as the Scottish National Blood Transfusion 
Services (SNBTS), National Health Services (NHS) or National Health Systems Blood and 
Transplant (NHSBT) will be an integral part of RM value chains because of their critical role in 
providing source materials, production of therapies and their linkages with SMEs for therapy 
development and clinical delivery.   
Contract manufacturing is the only RM activity generating revenue in the sector.  Although 
the manufacturing and scale-up business model as understood from pharmaceutical or 
biotechnology perspectives as a mature one, for RM it is still immature and developing and, 
because of scarcity of skills and facilities, costs are still very high.  A respondent from a CMO 
company reported that a contract manufacturer charges from £10 000 -20 000 per week for 
a clean room.  Equally onerous for RM SMEs is the fact that manufacturing optimisation 
learning costs are borne by them and not the CMO.  This is expensive given that it can take 
up to eight weeks to optimise a manufacturing protocol. 
4.4 Translational Services Business Model 
The Translational Services Business Model includes firms and organisations that provide 
specialist advice and coaching on regulation, clinical trial management, and technology and 
business management services.  The CGTC is a key provider of regulatory advisory services, 
technology, funding, and is also an innovation broker in the RM innovation ecosystem and so 
falls within this business model. As discussed earlier RM SMEs do not possess in-house 
capabilities for all their operations and they depend on inter-firm linkages with translational 
service providers in the RM value chain to acquire products and services critical for 
progressing therapies down the translational pathway.   
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The basis of this model is consultancy services and firms with expertise in certain aspects of 
the RM value chain, the first movers in the sector, have generated revenues by consulting for 
latecomer firms.  A cell manufacturing case we studied termed this business model “contract 
translation” because they contracted out on regulatory, clinical development and contract 
manufacturing for other players leveraging their first mover advantage in these capabilities 
(CEO, Cell Manufacturing Case, 2015).  However, due to high investment in infrastructure, 
technology and skills, and maintenance, publicly funded organisations tended to dominate 
this group.  They worked closely with academics and SMEs from pre-clinical work to clinical 
trials, assisting with early development work, organ collection (for tissue-based therapies), 
cell manufacture and clinical trials.  Publicly funded bodies are clear on their remit as reflected 
in this quote: 
“We are a public sector organisation, we’re not here to make money, we are 
here to do two things …one is principally to provide a service for patients … 
and to facilitate development of new cell therapies which might be service 
based like autologous therapies. … [we are] not in competition with private 
companies, we’re not trying to be. What we do is facilitate development of 
the private sector in this space…” (Director with a National Blood Transfusion 
Service body, 2015). 
Market failure explains the dominance of public sector organisations because of lack of 
market led long-term investment for radical innovation with an uncertain future and no clear 
route to market.  The government recognised that the high cost of investment in cGMP 
facilities was a translational impediment for RM therapy development and allocated £55 
million over four years to the Cell and Gene Therapy Catapult to build a cGMP facility in 
Stevenage.  In 2014, an additional £12 million was made available through UK Government, 
and a further £30 million was allocated in 2017 for investment in three new hospital based 
sites for new Advanced Therapy Treatment Centres.  Our study however shows that this 
public investment in innovation infrastructure had unintended consequences on a cell 
manufacturing case that we studied.  They argued that they could not compete with a more 
resourced CGTC, which raises an important issue of balancing public investment in innovation 
infrastructure and ensuring that public funded institutions do not crowd out innovative SMEs 
in the same space, as discussed in section 4.3. 
4.5 Virtual business model 
The Virtual Business Model applies to pre-revenue SMEs and university spinouts, which 
strategically defer investment in people, technology and infrastructure at early therapy 
development stages to reduce core-funding requirements.  They do this to stretch research 
and development funding and move therapy development as far down the translational 
pathway as possible.  One case currently using the Virtual Business Model described it as: 
“So the [virtual] business model is that we pay for the expertise, we use….so 
we have no full time employees … In terms of laboratories the research needed 
to bring the product forward was undertaken in my lab using funding initially 
from the [philanthropic funder] and then from [public funders] … We also have 
some in-vivo work, some preclinical work done in London… So we don’t own 
any labs, we don’t rent any labs we simply pay for services whether its 
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regulatory or laboratory or research or technical or advisory, that’s what we 
mean by a virtual company. …. But the main driver was to keep costs down … 
the last thing I wanted … was to grow the company too quickly and have to 
close down because it was too expensive just to keep the company going” 
(CEO, early stage Cell Therapy case, 2015) 
For business model theory, this is an interesting finding for emerging life sciences sectors, 
where financial strategy drives the architecture and structure of an enterprise to be 
dependent on established early stage RM value chain networks and linkages.  This strategy is 
feasible for situations where, according to Gereffi et al (2005), technology can be codified and 
tacit knowledge is not dominant.  The case quoted above was possible because the cell 
therapy firm can use codified standard processes in cell manufacture and the surgical process 
involving injecting cells into tissue.  Our analysis suggests that the Virtual Business Model may 
be transitory as its key driver is scarce financial resources for early therapy development 
phases.  We would argue that once some products are on the market firms would want to 
control as much of the value chain as they can.  Enterprises using the Virtual Business Model 
depend entirely on linkages with their suppliers and as such, the coordination costs would be 
too high given the need to manage scheduling and logistics.  Our study shows firms are using 
this model to access manufacturing scale up, quality assurance, regulatory and clinical trial 
advisory services.   
4.6 Fully integrated business model 
The fully integrated business model at this stage is a theoretical construct incorporating the 
previous five models, where the firm or organisation would control activities from the 
laboratory to the patient.  This implies that the firm or organisation is able to bring in-house 
predominantly tacit knowledge capabilities characteristic of these innovative technologies, in 
line with Gereffi et al’s (2005) hierarchy of value chain governance, given that RM products 
are complex, their specifications are largely not yet codified, knowledge is tacit, and there are 
no capable suppliers.  All the 10 cases we studied had neither the financial resources nor in-
house capabilities to use this business model. 
In this model, the firm develops RM therapies, manages IP, engages in managing clinical 
trials and related manufacturing scale up, acquires market authorisation and gets clinical 
adoption.  A cell therapy case that had raised substantial amounts of funding on the equity 
market described their intended business model as: 
“… we are a stem cell development business… [we] develop stem cell science, 
and … translate them into commercial therapies. … the business model … is to 
take a number of selected stem cell based therapeutic candidates through 
pre-clinical and clinical development, … to realise the commercial potential of 
those therapies” (Finance Director Cell Therapy Development Case, 2015). 
This pre-revenue cell therapy development case’s strategy was based on the end-point of 
having a Fully Integrated Business Model. However pragmatically they behaved to some 
extent as a hybrid Virtual Business Model and contracted out development, clinical trial work 
and manufacturing.  They were classed as a hybrid Virtual Business Model because, even 
though they contracted out some services, they had core staff who did the bulk of the 
development work.  During the financial downturn of 2008, they had to lay off staff to reduce 
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their cash burn rate, because they were still a pre-revenue firm.  In future, they plan to bring 
in-house most activities when their cGMP RM facility is completed.  When they contracted-
out services, they retained and protected their intellectual property and trade secrets through 
contractual agreements.  This case shows that there will be various forms of the Integrated 
Business Model as some activities are brought in-house, or where it is cheaper contracted-
out. 
5. Conclusion  
We argued that ex-poste application of traditional business model approaches are limited in 
their usefulness for RM.  However, we acknowledged that the business model notion could 
be a useful heuristic tool for sense making in designing context-specific policy and practice, 
as well as investment interventions.  We identified, characterised and analysed six interlinked 
business models whose evolving value chains still have gaps especially in healthcare settings.  
All six-business models are all still pre-revenue, except for manufacturing and scale-up, and 
as a result, all the business models are in a state of flux. This presents scalability and 
sustainability challenges for the sector. 
As RM business models evolve, crowding-out tensions between the public and private sector 
may occur, and will need to be resolved timeously.  Investment in manufacturing will be 
critical for the sector.  Early integration into big pharma may be a hard sell because of 
differences in skills sets and business models.  What may emerge initially could be “orphan 
drug” type sectors operating in parallel with the hospital exemptions. Designing policy and 
regulation that incentivises early stabilisation of the sector may promote faster development 
of the RM innovation ecosystem.  This can build on current government investments that are 
bridging value chain gaps through innovation infrastructure and innovation brokers such as 
CGTC, clinical adoption centres, doctoral training centres, and RM Manufacturing centres of 
excellence. The public sector is best placed to invest in de-risking RM technology development 
and adoption early stages, and serves as a key signal to other traditional investors. Pre-
emptive policy design that supports value chain upgrading paying particular attention to 
short, medium and long-term sustainability of the RM innovation eco-system, especially 
evolution of a broad base of SMEs that can take over when public funding is withdrawn will 
be complex. A proportionate and adaptive regulatory environment would be critical to 
supporting evolving business models even as value chain upgrading occurs. 
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